B+
Bull case
20%
Probability
Target price
$88.77
Analysis reference price unavailable
Analysis 2026-01-10 · RankAlpha Sentiment AI
CGON
CG OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$63.80
Analysis reference price unavailable
Analysis 2026-01-10 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$38.84
Analysis reference price unavailable
Analysis 2026-01-10 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-10
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.3
Score
AI commentary
Market sentiment appears mixed-to-cautious with several third-party price-targets showing a wide range, indicating dispersion among analysts [#SERP-1] and aggregator sites showing varied medians [#SERP-3]. Short-term tone is event-driven and sensitive to clinical/operational news; investor focus is on binary milestones and cash runway. External targets were consulted only as a reference against the anchor-driven scenarios [#SERP-2].
RankAlpha Sentiment AI - 2026-01-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventClinical data readout (assumed window end)High impact
Potential binary clinical readout or cohort update that would drive large directional moves; date is an assumed end-of-window where specifics are not public—assumption noted here [#SERP-1].
2026-04-10catalystNear-term operational / earnings updateHigh impact
Quarterly operational or cash-runway update expected in the near term; could materially re-rate shares if guidance deviates from current expectations (assumed date used where no public date available) [#SERP-3].
2027-01-10catalystPartnership / regulatory progressHigh impact
Potential longer-term value creation from partnerships, licensing, or regulatory milestones; timing estimated conservatively when not publicly disclosed.
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-10 • Updated nightlySource: Internal modelMethodology